This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Drugs

Cramer Answers Twitter Questions on Mobileye, Opko Health, Alcoa

Jim Cramer answers viewers' Twitter questions from the floor of the New York Stock Exchange.

01/26/15 - 12:15 PM EST

Biotech Stock Mailbag: Arena Pharma, Agenus, EnteroMedics

Biotech columnist Adam Feuerstein answers readers' questions about health care.

01/23/15 - 06:00 AM EST

Try Jim Cramer's Action Alerts PLUS
Three Companies That Should Benefit From a Stronger U.S. Dollar Three Companies That Should Benefit From a Stronger U.S. Dollar

Three Companies That Should Benefit From a Stronger U.S. Dollar

Xavier Smith, portfolio manager for the Centre Global Select Equity Fund, makes a case for Bridgestone, Tata Motors and Novo Nordisk.

01/20/15 - 01:41 PM EST

Express Scripts CEO: Amgen, Regeneron Among Targets for Drug Discounting

Express Scripts CEO: Amgen, Regeneron Among Targets for Drug Discounting

Express Scripts CEO George Paz doesn't mince words about the need to cap specialty drug pricing during his talk Tuesday at the J.P. Morgan Healthcare Conference.

01/13/15 - 12:46 PM EST

8 Biotech Stock Controversies Emerging From 'JPM15' Conference

8 Biotech Stock Controversies Emerging From 'JPM15' Conference

The J.P. Morgan Healthcare Conference is in the rear-view mirror, but issues, controversies and questions raised during the annual gathering of the biotech sector tribe will linger through the year.

01/20/15 - 10:18 AM EST

Growers Struggle With Oversupply of Legal Pot in Washington State

Growers Struggle With Oversupply of Legal Pot in Washington State

Prices are starting to come down in Washington state's licensed pot shops, but due to the glut, growers are — surprisingly — struggling to sell their marijuana.

01/16/15 - 10:27 AM EST

Advaxis CEO: Institutional Interest in Immunotherapy Driving Stock

Advaxis CEO: Institutional Interest in Immunotherapy Driving Stock

Advaxis has seen its shares surge higher in the past month due to increased institutional interest and an optimistic response from investors, said the company's CEO Dan O'Connor.

01/15/15 - 04:05 PM EST

Jim Cramer on Stocks: Here Are the Two Best CEOs You Can Bank On

Jim Cramer on Stocks: Here Are the Two Best CEOs You Can Bank On

They're both named Bob.

01/14/15 - 10:06 AM EST

Sagent Pharmaceuticals is in Talks with Potential Targets

Sagent Pharmaceuticals is in Talks with Potential Targets

  • Tickers in this article:
  • SGNT

Buys in the injectables space are on the table for the pharmaceutical company.

01/14/15 - 08:31 AM EST

Impax Laboratories Expects More M&A After Latest Deal Closes

Impax Laboratories Expects More M&A After Latest Deal Closes

  • Tickers in this article:
  • IPXL

Chief executive says the pharma company is hunting for its next deal after its $700 million Tower buy.

01/14/15 - 08:21 AM EST

AmerisourceBergen Acquires MWI for $2.5 Billion; Shire Pays $5.2 Billion for NPS Pharmaceuticals

AmerisourceBergen Acquires MWI for $2.5 Billion; Shire Pays $5.2 Billion for NPS Pharmaceuticals

AmerisourceBergen announced on Jan. 12 that it inked a deal to acquire Boise, Idaho-based MWI Veterinary Supply for $2.5 billion.

01/12/15 - 03:32 PM EST

BioMarin Shows Up Rival Sarepta During 'JPM15' Investor Presentation

BioMarin Shows Up Rival Sarepta During 'JPM15' Investor Presentation

Included in Bienaime's investor presentation is two slides making a direct data comparison between BioMarin's (soon to be) Duchenne muscular dystrophy drug drisapersen and Sarepta's competing DMD drug eteplirsen.

01/12/15 - 02:38 PM EST

Roche Buys Stake in Foundation Medicine to Widen Cancer Offerings

Roche Buys Stake in Foundation Medicine to Widen Cancer Offerings

  • Tickers in this article:
  • FMI

Swiss pharmaceutical company Roche Holding said it is taking a majority stake in U.S. based-Foundation Medicine in a deal worth more than $1 billion.

01/12/15 - 12:44 PM EST

Jim Cramer: Shire-NPS Deal Verifies Strategy of Many Biotechs

Jim Cramer: Shire-NPS Deal Verifies Strategy of Many Biotechs

  • Tickers in this article:
  • NPSP

Shire has agreed to buy U.S. group NPS Pharmaceuticals for $5.2 billion in an all-cash deal.

01/12/15 - 11:51 AM EST

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 17,678.70 +6.10 0.03%
S&P 500 2,057.09 +5.27 0.26%
NASDAQ 4,771.7630 +13.8840 0.29%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs